TG Therapeutics, Inc.
TGTX
$30.63
-$1.04-3.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 531.90M | 454.07M | 386.39M | 329.00M | 264.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 531.90M | 454.07M | 386.39M | 329.00M | 264.79M |
| Cost of Revenue | 77.97M | 59.22M | 48.59M | 38.49M | 30.94M |
| Gross Profit | 453.93M | 394.85M | 337.80M | 290.52M | 233.85M |
| SG&A Expenses | 208.25M | 186.85M | 170.05M | 154.30M | 146.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 429.12M | 368.22M | 326.57M | 287.08M | 265.30M |
| Operating Income | 102.78M | 85.85M | 59.82M | 41.93M | -505.00K |
| Income Before Tax | 87.75M | 66.11M | 41.74M | 25.59M | -13.89M |
| Income Tax Expenses | -359.72M | 5.65M | 2.59M | 2.21M | 479.00K |
| Earnings from Continuing Operations | 447.47 | 60.46 | 39.15 | 23.38 | -14.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 447.47M | 60.46M | 39.15M | 23.38M | -14.36M |
| EBIT | 102.78M | 85.85M | 59.82M | 41.93M | -505.00K |
| EBITDA | 102.83M | 85.89M | 59.87M | 42.00M | -408.00K |
| EPS Basic | 3.08 | 0.41 | 0.27 | 0.16 | -0.10 |
| Normalized Basic EPS | 0.38 | 0.28 | 0.18 | 0.11 | -0.06 |
| EPS Diluted | 2.78 | 0.37 | 0.24 | 0.14 | -0.11 |
| Normalized Diluted EPS | 0.34 | 0.26 | 0.16 | 0.10 | -0.06 |
| Average Basic Shares Outstanding | 584.08M | 583.76M | 581.75M | 581.28M | 579.13M |
| Average Diluted Shares Outstanding | 646.57M | 646.29M | 643.15M | 626.59M | 609.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |